These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 36107354)
1. TM2, a novel semi-synthetic taxoid, exerts anti-MDR activity in NSCLC by inhibiting P-gp function and stabilizing microtubule polymerization. Jia L; Gao X; Fang Y; Zhang H; Wang L; Tang X; Yang J; Wu C Apoptosis; 2022 Dec; 27(11-12):1015-1030. PubMed ID: 36107354 [TBL] [Abstract][Full Text] [Related]
2. 5-(3,4,5-trimethoxybenzoyl)-4-methyl-2-(p-tolyl) imidazol (BZML) targets tubulin and DNA to induce anticancer activity and overcome multidrug resistance in colorectal cancer cells. Bai Z; Liu X; Guan Q; Ding N; Wei Q; Tong B; Zhao M; Zhang W; Ma L Chem Biol Interact; 2020 Jan; 315():108886. PubMed ID: 31682804 [TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo anti-tumour effects of MPT0B014, a novel derivative aroylquinoline, and in combination with erlotinib in human non-small-cell lung cancer cells. Tsai AC; Pai HC; Wang CY; Liou JP; Teng CM; Wang JC; Pan SL Br J Pharmacol; 2014 Jan; 171(1):122-33. PubMed ID: 24116948 [TBL] [Abstract][Full Text] [Related]
4. Reversing Multidrug Resistance in Chemo-resistant Human Lung Adenocarcinoma (A549/DOX) Cells by Algerian Propolis Through Direct Inhibiting the P-gp Efflux-pump, G0/G1 Cell Cycle Arrest and Apoptosis Induction. Kebsa W; Lahouel M; Rouibah H; Zihlif M; Ahram M; Abu-Irmaileh B; Mustafa E; Al-Ameer HJ; Al Shhab M Anticancer Agents Med Chem; 2018; 18(9):1330-1337. PubMed ID: 30088453 [TBL] [Abstract][Full Text] [Related]
5. P-glycoprotein-evading anti-tumor activity of a novel tubulin and HSP90 dual inhibitor in a non-small-cell lung cancer model. Zhang Q; Zhai S; Li L; Li X; Jiang C; Zhang C; Yan B J Pharmacol Sci; 2014; 126(1):66-76. PubMed ID: 25185500 [TBL] [Abstract][Full Text] [Related]
6. YAN, a novel microtubule inhibitor, inhibits P-gp and MRP1 function and induces mitotic slippage followed by apoptosis in multidrug-resistant A549/Taxol cells. Gao M; Liu T; Li J; Guan Q; Wang H; Yan S; Li Z; Zuo D; Zhang W; Wu Y Toxicol In Vitro; 2020 Dec; 69():104971. PubMed ID: 32805372 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic strategies to overcome taxane resistance in cancer. Das T; Anand U; Pandey SK; Ashby CR; Assaraf YG; Chen ZS; Dey A Drug Resist Updat; 2021 Mar; 55():100754. PubMed ID: 33691261 [TBL] [Abstract][Full Text] [Related]
8. A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro. Cai P; Lu P; Sharom FJ; Fang WS Cancer Lett; 2013 Dec; 341(2):214-23. PubMed ID: 23941826 [TBL] [Abstract][Full Text] [Related]
9. Identification of a lathyrane-type diterpenoid EM-E-11-4 as a novel paclitaxel resistance reversing agent with multiple mechanisms of action. Liu Q; Cai P; Guo S; Shi J; Sun H Aging (Albany NY); 2020 Feb; 12(4):3713-3729. PubMed ID: 32108588 [TBL] [Abstract][Full Text] [Related]
10. BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe. Bai Z; Gao M; Zhang H; Guan Q; Xu J; Li Y; Qi H; Li Z; Zuo D; Zhang W; Wu Y Cancer Lett; 2017 Aug; 402():81-92. PubMed ID: 28576750 [TBL] [Abstract][Full Text] [Related]
11. MAY, a novel tubulin inhibitor, induces cell apoptosis in A549 and A549/Taxol cells and inhibits epithelial-mesenchymal transition in A549/Taxol cells. Du J; Li J; Gao M; Guan Q; Liu T; Wu Y; Li Z; Zuo D; Zhang W; Wu Y Chem Biol Interact; 2020 May; 323():109074. PubMed ID: 32217108 [TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory Protein from Ganoderma microsporum Induces Pro-Death Autophagy through Akt-mTOR-p70S6K Pathway Inhibition in Multidrug Resistant Lung Cancer Cells. Chiu LY; Hu ME; Yang TY; Hsin IL; Ko JL; Tsai KJ; Sheu GT PLoS One; 2015; 10(5):e0125774. PubMed ID: 25946033 [TBL] [Abstract][Full Text] [Related]
13. An ester derivative of tenacigenin B from Marsdenia tenacissima (Roxb.) Wight et Arn reversed paclitaxel-induced MDR in vitro and in vivo by inhibiting both P-gp and MRP2. Wu ZL; Chen Y; Qu Z; Wu GY; He XF; Huang JW; Meng QQ; Hu YH; Shen XL; Yang RY; Hu YJ J Ethnopharmacol; 2022 Aug; 294():115353. PubMed ID: 35533911 [TBL] [Abstract][Full Text] [Related]
15. Hypoxia Induces Multidrug Resistance via Enhancement of Epidermal Growth Factor-Like Domain 7 Expression in Non-Small Lung Cancer Cells. Shen X; Zhi Q; Wang Y; Li Z; Zhou J; Huang J Chemotherapy; 2017; 62(3):172-180. PubMed ID: 28351036 [TBL] [Abstract][Full Text] [Related]
16. SERCA and P-glycoprotein inhibition and ATP depletion are necessary for celastrol-induced autophagic cell death and collateral sensitivity in multidrug-resistant tumor cells. Xu SW; Law BYK; Qu SLQ; Hamdoun S; Chen J; Zhang W; Guo JR; Wu AG; Mok SWF; Zhang DW; Xia C; Sugimoto Y; Efferth T; Liu L; Wong VKW Pharmacol Res; 2020 Mar; 153():104660. PubMed ID: 31982489 [TBL] [Abstract][Full Text] [Related]
17. Asiatic Acid (AA) Sensitizes Multidrug-Resistant Human Lung Adenocarcinoma A549/DDP Cells to Cisplatin (DDP) via Downregulation of P-Glycoprotein (MDR1) and Its Targets. Cheng Q; Liao M; Hu H; Li H; Wu L Cell Physiol Biochem; 2018; 47(1):279-292. PubMed ID: 29768255 [TBL] [Abstract][Full Text] [Related]
18. Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function. Dai CL; Liang YJ; Chen LM; Zhang X; Deng WJ; Su XD; Shi Z; Wu CP; Ashby CR; Akiyama S; Ambudkar SV; Chen ZS; Fu LW Biochem Pharmacol; 2009 Aug; 78(4):355-64. PubMed ID: 19410561 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of ABT-751, a novel anti-mitotic agent able to overcome multi-drug resistance, in melanoma cells. Mahgoub TM; Jordan EJ; Mahdi AF; Oettl V; Huefner S; O'Donovan N; Crown J; Collins DM Cancer Chemother Pharmacol; 2024 May; 93(5):427-437. PubMed ID: 38226983 [TBL] [Abstract][Full Text] [Related]
20. Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein. Duran GE; Derdau V; Weitz D; Philippe N; Blankenstein J; Atzrodt J; Sémiond D; Gianolio DA; Macé S; Sikic BI Cancer Chemother Pharmacol; 2018 Jun; 81(6):1095-1103. PubMed ID: 29675746 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]